Science Daily: Pharmacology News

JULY 2, 2025

A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a virus to deliver a healthy copy of the OTOF gene into the inner ear, improving auditory function across all ten participants in the study. The therapy worked best in young children but still benefited adults, with one 7-year-old girl regaining almost full hearing.

Virus 277

Virus Therapies Research 277

BioPharma Drive: Drug Pricing

JULY 2, 2025

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

248

248

Drugs.com

JULY 2, 2025

WEDNESDAY, July 2, 2025 -- The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain formulations of amphetamine and methylphenidate, to warn.

FDA 284

FDA Drugs 284

Collaborative Drug

JULY 8, 2025

BURLINGAME, Calif. — July 8, 2025. Collaborative Drug Discovery (CDD) , the leading provider of data management solutions for the pharmaceutical and biotechnology industries, and deepmirror , the AI drug design platform that empowers chemists to focus on more promising drug molecules, today announced a strategic partnership integrating deepmirror with CDD Vault to enhance drug discovery.

Drugs 147

Drugs Pharmaceuticals 147

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

Clinical Trials

Chemical Biology and Drug Design

JULY 3, 2025

Computationally guided modifications of centaureidin led to the development of CA4, demonstrating enhanced antioxidant and antitumor activities. Molecular docking and in vitro assays confirm improved binding affinity and cytotoxicity, highlighting CA4's potential as a promising drug candidate for cancer therapy. ABSTRACT The development of novel therapeutic drugs with enhanced efficacy has gained significant attention in recent years.

Drug Development 100

Drug Development Drugs Therapies Production 100

Drug Target Review

JULY 1, 2025

Clinical trials are expensive, slow and often limited by outdated design constraints. Placebo arms, in particular, create ethical and logistical hurdles, especially in areas like rare disease and oncology. Digital twins offer a way forward. They offer patient-specific outcome predictions, generated using machine learning models trained on real historical clinical data.

Clinical Trials 99

Clinical Trials Trials FDA Disease 99

BioPharma Drive: Drug Pricing

JULY 1, 2025

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.

217

217

Drugs.com

JULY 8, 2025

TUESDAY, July 8, 2025 — More Florida teens are roaming the streets packing heat, a new study says.Handgun carrying among Florida middle and high school students increased by 65% between 2002 and 2022, researchers reported July 7 in the journal P.

Research 130

Research 130

New Drug Approvals

JULY 5, 2025

PALAZESTRANT CAS 2092925-89-6 OP-1250, VU35KM56Q4 449.6 g/mol, C 28 H 36 FN 3 O (1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-[4-(1-propylazetidin-3-yl)oxyphenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole (1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1-{4-[(1-propylazetidin-3- yl)oxy]phenyl}-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole Palazestrant (OP-1250) is an investigationa

Small Molecule 62

Small Molecule Clinical Trials Pharmacokinetics FDA 62

Chemical Biology and Drug Design

JULY 1, 2025

Two compounds, A16 and A17, were active against multidrug-resistant Mycobacterium tuberculosis isolates (PT-12 and PT-20), overcoming key resistance mutations in katG and rpoB, while cytotoxicity assays confirmed that they are non-toxic. A17 exhibited the highest antituberculosis activity, with molecular docking suggesting enoyl-[acyl-carrier-protein] reductase as a potential biological target.

Pharmacokinetics 100

Pharmacokinetics Drugs Therapies Research 100

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. However, R&D stakeholders are learning that GenAI underpinned by domain expertise also enables deep dives into the broader long-term potential of their investigational asset(s) as early as the preclinical phase.

Drug Development 64

Drug Development Drugs Animal Testing Engineering 64

Science Daily: Pharmacology News

JULY 1, 2025

Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into metabolic microscopes. The system distinguishes healthy regions, grades tumors, and forecasts MS flare-ups long before structural MRI can. Precision-medicine neurology just moved closer to reality.

Disease 227

Disease Engineering 227

BioPharma Drive: Drug Pricing

JULY 7, 2025

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less frequent dosing.

Treatment 147

Treatment Drugs 147

Drugs.com

JULY 1, 2025

TUESDAY, July 1, 2025 — Opioid addicts covered by Medicare and Medicaid are less likely to receive the mental health and substance use treatment that they need, a new study says. Addicts with public insurance receive more than twice as many.

Treatment 269

Treatment 269

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Perficient: Drug Development

JULY 8, 2025

In Adobe’s 2025 AI and Digital Trends report, one message rings loud and clear: the convergence of marketing and IT is essential to digital success. As AI becomes increasingly embedded in customer experience strategies, marketing and IT leaders must collaborate closely to unlock its full potential. The Rise of Agentic AI One of the most transformative ideas in the report is the rise of agentic AI, autonomous systems that collaborate across platforms to deliver hyper-personalized, real-time exper

52

52

Chemical Biology and Drug Design

JULY 1, 2025

Determination of binding ability of flavonoids/phenolic acids to HSA by affinity capillary electrophoresis and fluorescence spectroscopy. ABSTRACT The interaction of small molecule drugs with human serum albumin (HSA) after entering the human blood circulation system profoundly affects their distribution and absorption in the body, and further influences the activity.

Small Molecule 100

Small Molecule Drugs Research 100

Molecular Design

JULY 6, 2025

Here’s a photo from one of my exercise walks in Paramin and you can see the Caribbean Sea in the distance. This is perhaps my favourite view on the walk because it means that I’ve just got to the top of a particularly brutal hill (cars sometimes struggle to get to the top and on one occasion I watched a car fail miserably in four attempts) although you can’t always see the sea as clearly as in this photo.

Biochemical Assays 61

Biochemical Assays Biophysical Assays Targeted Protein Degradation Drugs 61

Science Daily: Pharmacology News

JULY 6, 2025

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over 12 months, whereas placebo patients worsened. Those with high-risk genes even saw cognitive gains, hinting at real disease-modifying power.

Disease 221

Disease 221

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

BioPharma Drive: Drug Pricing

JULY 7, 2025

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an on-time approval.

FDA 162

FDA Drugs 162

Drugs.com

JULY 7, 2025

MONDAY, July 7, 2025 — Radiation therapy to treat cancer might be a double-edged sword that increases the risk posed by other malignant tumors, a new study argues. While radiation is often used alone or in combination with other treatments to.

Therapies 236

Therapies Treatment 236

Drug Target Review

JULY 8, 2025

Dr Eleni Lagkadinou is on a mission to fast-track the future of cancer care. As Vice President of Oncology Early Development (OED) at AbbVie , she leads the charge on translating bold scientific ideas into real-world impact – and she’s doing it with a focus on some of the most tenacious cancers out there. With a background spanning drug development, clinical strategy and translational research, Eleni brings more than two decades of experience to the role.

Therapies 52

Therapies Science Drug Development Treatment 52

Crown Bioscience

JULY 1, 2025

Highly targeted antibody-drug conjugates (ADCs) combine an antibody with a cytotoxic payload, covalently attached via a chemical linker. These “ biological missiles ” represent an exciting new advance in anti-cancer therapies and are one of the fastest-growing segments in oncology drug development. Due to their complex make-up and multiple components, analysis of their chemistry and functionality is challenging, requiring advanced assays and techniques for effective study and characterization.

Drugs 52

Drugs Drug Development Therapies Research 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

addgene Blog

JULY 8, 2025

This post was written by Alfonso Timoneda, with significant contributions from Robert Hurt and Mohamed Soufi. So you’ve learned about the Modular Cloning (MoClo) system and what it can do for you, and you’ve chosen one of the MoClo kits available through Addgene that suits your experimental purposes. But what now? MoClo really simplifies vector construction by combining restriction and ligation steps together in the same tube at the same time, however, it can prove itself to be quite the mental

52

52

Science Daily: Pharmacology News

JULY 2, 2025

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers than our primate cousins. The change affects a protein used by immune cells to kill tumors—except in humans, it’s vulnerable to being shut down by an enzyme that tumors release. This flaw may be one reason treatments like CAR-T don’t work as well on solid tumors.

Treatment 215

Treatment Research 215

BioPharma Drive: Drug Pricing

JULY 1, 2025

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray into pivotal testing.

Drugs 147

Drugs 147

Drugs.com

JULY 7, 2025

MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and Prevention (CDC). This marks a change from the.

Vaccine 257

Vaccine Disease 257

Drug Target Review

JULY 7, 2025

Non-human primates (NHPs), such as macaques and cynomolgus monkeys, have long served as a cornerstone in preclinical drug development due to their close genetic, anatomical and physiological resemblance to humans. Their unique suitability has made them valuable for evaluating pharmacokinetics, toxicology and safety in drug candidates before human clinical trials.

Drug Research 52

Drug Research Research Animal Testing Drugs 52

Quanticate

JULY 3, 2025

Imagine being asked to join a clinical trial, but the nearest site is two hours away and you care for an elderly parent while working full-time. The burden of travel alone could be enough to say no. That’s the challenge decentralised clinical trials (DCTs) aim to solve.

Clinical Trials 52

Clinical Trials Trials 52

Crown Bioscience

JULY 3, 2025

Often referred to as “magic bullets” or “biological missiles”, antibody-drug conjugates (ADCs) are one of the most promising advances in targeted cancer therapy, as they allow potent anti-cancer agents to be selectively delivered to cancer cells, while minimizing damage to healthy cells. This unique class of hybrid drugs typically contain a monoclonal antibody (mAbs) and a cytotoxic drug, attached via a chemical linker, combining “ both the advantages of highly specific targeting ability and hig

Drugs 52

Drugs Therapies 52

Science Daily: Pharmacology News

JULY 1, 2025

Researchers reviewing nearly 300 top-tier ADHD drug trials found that half skipped the rigorous, expert-led evaluations needed to rule out other conditions like depression or schizophrenia. With diagnoses often made by unqualified staff—or even by computer—many participants may not have actually had ADHD, casting doubt on study outcomes that shape treatment guidelines.

Trials 188

Trials Drug Trials Treatment Research 188

BioPharma Drive: Drug Pricing

JULY 7, 2025

One analyst described Cogent’s data as a “home run scenario” for bezuclastinib, which the company is positioning as a competitor to Blueprint Medicines’ Ayvakit.

Disease 147

Disease Drugs 147

Drugs.com

JULY 8, 2025

TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says.Corticosteroids are commonly prescribed to alleviate cancer-related symptoms in patients w.

Treatment 147

Treatment Drugs 147